Biopharma Daily Stock Updates - 02/08/21

$XBI $173.99 +4% 📈


$EIGR +12% Phase 2 covid data published in Lancet Respiratory Medicine journal. source


SRNE +18% Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic. source

$RGNX +5% Presented positive interim data for RGX-121 at WorldSymposium. source

$SUPN +5% resubmits NDA for SPN-812 for ADHD in pediatric patients. source

$SAVA +35% updates regarding end of phase 2 meeting and 2021 milestones. source

$LCTX +12% Entered into licensing agreement with med device company; will collab on clinical trials and use their PDI platform. source

$CUE +9% Initiated phase 1 combo w/ Keytruda as First-line Treatment for HPV+ Recurrent/Metastatic Head and Neck Cancer. source

$QURE +8% Positive Recommendation from Data Safety Monitoring Board of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease. source

$ERYP -15% TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis per IDMC. Final results expected Q4 2021. source

$AVRO +13% 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato® Gene Therapy Platform in Fabry Disease Phase 2 Trial. source


$ETON +2% Sale of Neurology Portfolio. source


*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.